Business
Darnatein to Present at 14th International BMP Conference Highlighting Advances in Regenerative Biologics
Darnatein, a subsidiary of OSR Holdings, Inc. (NASDAQ: OSRH), a biotechnology company advancing design-augmented biologics, announced today that it will present scientific data at the 14th International Bone Morphogenetic Protein (BMP) Conference, taking place May 2–6, 2025, at the University of Pennsylvania in Philadelphia.
About this update from Osr Holdings, Inc.
[{"type":"text","content":"PHILADELPHIA, May 2, 2025 /PRNewswire/ -- Darnatein, a subsidiary of OSR Holdings, Inc. (NASDAQ: OSRH), a biotechnology company advancing design-augmented biologics, announced today that it will present scientific data at the 14th International Bone Morphogenetic Protein (BMP) Conference, taking place May 2–6, 2025, at the University of Pennsylvania in Philadelphia.","length":368,"tagName":"p"},{"type":"image","alt":"OSR Holdings logo (PRNewsfoto/OSR Holdings)","displaySize":"","headline":null,"caption":"OSR Holdings logo (PRNewsfoto/OSR Holdings)","className":"","disableSlideshowImg":false,"size":{"original":{"width":334,"height":277,"url":"https://media.zenfs.com/en/prnewswire.com/d1cf26310f8a0d3a1f4f003318d5e702"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/cTh6l6BCVhUkYFTe3KonaA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTUzMTtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/d1cf26310f8a0d3a1f4f003318d5e702","width":334,"height":277}},"href":"https://mma.prnewswire.com/media/2393302/OSR_Holdings_logo_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"The BMP Conference brings together leading global researchers to explore the latest breakthroughs in BMP-related biology and regenerative medicine. This year's program highlights novel technologies and fundamental research in tissue and organ regeneration. (https://www.14thbmpconference2025.com/)","length":301,"tagName":"p"},{"type":"text","content":"Dr. Senyon "Teddy" Choe, CEO of Darnatein, will deliver a scientific presentation on May 3, titled:"Design-Augmented Synthetic BMP Chimeras as Super-Agonists for Bone and Cartilage Regeneration."","length":216,"tagName":"p"},{"type":"text","content":"The presentation will showcase Darnatein's proprietary platform technology that has led to the development of DRT-101 and DRT-102, two novel biologic candidates engineered to function as BMP super-agonists. DRT-101 with good preclinical safety profiles is being developed for joint cartilage regeneration, while DRT-102 is focused on spinal bone repair.","length":357,"tagName":"p"},{"type":"text","content":""This presentation reflects Darnatein's growing leadership in synthetic regenerative biologics," said Dr. Choe. "Our DA Biologics platform is enabling the creation of highly potent, next-generation growth factors...